Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 368

1.

What treatment works best for restless legs syndrome? Meta-analyses of dopaminergic and non-dopaminergic medications.

Hornyak M, Scholz H, Kohnen R, Bengel J, Kassubek J, Trenkwalder C.

Sleep Med Rev. 2014 Apr;18(2):153-64. doi: 10.1016/j.smrv.2013.03.004. Epub 2013 Jun 6. Erratum in: Sleep Med Rev. 2014 Aug;18(4):367-8.

PMID:
23746768
2.

Dopamine agonists for restless legs syndrome.

Scholz H, Trenkwalder C, Kohnen R, Riemann D, Kriston L, Hornyak M.

Cochrane Database Syst Rev. 2011 Mar 16;(3):CD006009. doi: 10.1002/14651858.CD006009.pub2. Review.

PMID:
21412893
3.

Levodopa for restless legs syndrome.

Scholz H, Trenkwalder C, Kohnen R, Riemann D, Kriston L, Hornyak M.

Cochrane Database Syst Rev. 2011 Feb 16;(2):CD005504. doi: 10.1002/14651858.CD005504.pub2. Review.

PMID:
21328278
4.

Where dopamine meets opioids: a meta-analysis of the placebo effect in restless legs syndrome treatment studies.

Fulda S, Wetter TC.

Brain. 2008 Apr;131(Pt 4):902-17. Epub 2007 Oct 11. Review.

PMID:
17932100
5.

Interventions for chronic kidney disease-associated restless legs syndrome.

Gopaluni S, Sherif M, Ahmadouk NA.

Cochrane Database Syst Rev. 2016 Nov 7;11:CD010690. Review.

PMID:
27819409
6.

Efficacy and safety of dopamine agonists in restless legs syndrome.

Hornyak M, Trenkwalder C, Kohnen R, Scholz H.

Sleep Med. 2012 Mar;13(3):228-36. doi: 10.1016/j.sleep.2011.09.013. Epub 2012 Jan 27. Review.

PMID:
22281001
7.

The long-term treatment of restless legs syndrome/Willis-Ekbom disease: evidence-based guidelines and clinical consensus best practice guidance: a report from the International Restless Legs Syndrome Study Group.

Garcia-Borreguero D, Kohnen R, Silber MH, Winkelman JW, Earley CJ, Högl B, Manconi M, Montplaisir J, Inoue Y, Allen RP.

Sleep Med. 2013 Jul;14(7):675-84. doi: 10.1016/j.sleep.2013.05.016.

8.

Pharmacologic therapy for primary restless legs syndrome: a systematic review and meta-analysis.

Wilt TJ, MacDonald R, Ouellette J, Khawaja IS, Rutks I, Butler M, Fink HA.

JAMA Intern Med. 2013 Apr 8;173(7):496-505. doi: 10.1001/jamainternmed.2013.3733. Review.

PMID:
23460396
9.

Treatment for Restless Legs Syndrome [Internet].

Wilt TJ, MacDonald R, Ouellette J, Tacklind J, Khawaja I, Rutks I, Butler M, Fink HA.

Rockville (MD): Agency for Healthcare Research and Quality (US); 2012 Nov.

10.

Opioids for restless legs syndrome.

de Oliveira CO, Carvalho LB, Carlos K, Conti C, de Oliveira MM, Prado LB, Prado GF.

Cochrane Database Syst Rev. 2016 Jun 29;(6):CD006941. doi: 10.1002/14651858.CD006941.pub2. Review.

PMID:
27355187
11.

A mixed treatment comparison of gabapentin enacarbil, pramipexole, ropinirole and rotigotine in moderate-to-severe restless legs syndrome.

Sun Y, van Valkenhoef G, Morel T.

Curr Med Res Opin. 2014 Nov;30(11):2267-78. doi: 10.1185/03007995.2014.946124. Epub 2014 Jul 31.

PMID:
25050588
13.

Restless legs syndrome in the older adult: diagnosis and management.

Milligan SA, Chesson AL.

Drugs Aging. 2002;19(10):741-51. Review.

PMID:
12390051
14.

Randomized trials of dopamine agonists in restless legs syndrome: a systematic review, quality assessment, and meta-analysis.

Zintzaras E, Kitsios GD, Papathanasiou AA, Konitsiotis S, Miligkos M, Rodopoulou P, Hadjigeorgiou GM.

Clin Ther. 2010 Feb;32(2):221-37. doi: 10.1016/j.clinthera.2010.01.028. Review.

PMID:
20206780
15.

Relation of the International Restless Legs Syndrome Study Group rating scale with the Clinical Global Impression severity scale, the restless legs syndrome 6-item questionnaire, and the restless legs syndrome-quality of life questionnaire.

Allen R, Oertel W, Walters A, Benes H, Schollmayer E, Grieger F, Moran K, Kohnen R.

Sleep Med. 2013 Dec;14(12):1375-80. doi: 10.1016/j.sleep.2013.09.008. Epub 2013 Oct 18.

PMID:
24246378
16.

Restless legs syndrome: pathophysiology and modern management.

Nagandla K, De S.

Postgrad Med J. 2013 Jul;89(1053):402-10. doi: 10.1136/postgradmedj-2012-131634. Epub 2013 Mar 22. Review.

PMID:
23524988
17.

Iron for restless legs syndrome.

Trotti LM, Bhadriraju S, Becker LA.

Cochrane Database Syst Rev. 2012 May 16;(5):CD007834. doi: 10.1002/14651858.CD007834.pub2. Review.

19.

Effect of non-ergot dopamine agonists on health-related quality of life of patients with restless legs syndrome.

Talati R, Phung OJ, Mather J, Coleman CI.

Ann Pharmacother. 2009 May;43(5):813-21. doi: 10.1345/aph.1L673. Epub 2009 Apr 28.

PMID:
19401472
20.

ADMET considerations for restless leg syndrome drug treatments.

de Biase S, Merlino G, Lorenzut S, Valente M, Gigli GL.

Expert Opin Drug Metab Toxicol. 2012 Oct;8(10):1247-61. doi: 10.1517/17425255.2012.708023. Epub 2012 Jul 18. Review.

PMID:
22808933

Supplemental Content

Support Center